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Abstract
Osteosarcoma (OS) is the most common primary bone cancer exhibiting high genomic in-
stability. This genomic instability affects multiple genes and microRNAs to a varying extent
depending on patient and tumor subtype. Massive research is ongoing to identify genes
including their gene products and microRNAs that correlate with disease progression and
might be used as biomarkers for OS. However, the genomic complexity hampers the iden-
tiﬁcation of reliable biomarkers. Up to now, clinico-pathological factors are the key deter-
minants to guide prognosis and therapeutic treatments. Each day, new studies about OS
are published and complicate the acquisition of information to support biomarker discov-
ery and therapeutic improvements. Thus, it is necessary to provide a structured and anno-
tated view on the current OS knowledge that is quick and easily accessible to researchers
of the ﬁeld. Therefore, we developed a publicly available database and Web interface that
serves as resource for OS-associated genes and microRNAs. Genes and microRNAs were
collected using an automated dictionary-based gene recognition procedure followed by
manual review and annotation by experts of the ﬁeld. In total, 911 genes and 81
microRNAs related to 1331 PubMed abstracts were collected (last update: 29 October
2013). Users can evaluate genes and microRNAs according to their potential prognostic
and therapeutic impact, the experimental procedures, the sample types, the biological
contexts and microRNA target gene interactions. Additionally, a pathway enrichment ana-
lysis of the collected genes highlights different aspects of OS progression. OS requires
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pathways commonly deregulated in cancer but also features OS-speciﬁc alterations like
deregulated osteoclast differentiation. To our knowledge, this is the ﬁrst effort of an OS
database containing manual reviewed and annotated up-to-date OS knowledge. It might
be a useful resource especially for the bone tumor research community, as speciﬁc infor-
mation about genes or microRNAs is quick and easily accessible. Hence, this platform can
support the ongoing OS research and biomarker discovery.
Database URL: http://osteosarcoma-db.uni-muenster.de
Introduction
Osteosarcoma (OS) the most common primary malignant
tumor of bone frequently affects children and young ado-
lescents (1). It is a complex disease with manifold numer-
ical and structural genomic alterations affecting multiple
genes to a varying extent (2). Patients without clinical signs
of systematic spread show 5-year survival rates of 60–80%
(3), whereas patients with metastasis at diagnosis exhibit
5-year survival rates of 20–30%. Since 1980, the prognosis
of patients has more or less stagnated and no significant
therapy improvements have been achieved (4).
Massive research in the field of OS is ongoing to assess
the prognostic and therapeutic impact of possible bio-
markers and altered molecular pathways. For instance,
several studies detected frequent genomic alterations of the
tumor suppressor genes TP53 and RB1 in OS and corre-
lated these findings with disease outcome (5–7). Other
studies identified p-glycoprotein and ezrin that influence
the response to chemotherapy and metastatic spread, re-
spectively (8). Recently, attention has been paid to the
value of small non-coding microRNAs in the pathogenesis
of OS, e.g. the miR-1792 cluster (9, 10) and miR-9-5p
(11, 12). MicroRNAs represent interesting biomarkers for
OS, as they are able to simultaneously regulate hundreds
of target genes and several molecular pathways
(13).However, the prognostic and therapeutic significance
neither for distinct genes including their gene products nor
for microRNAs has been determined in controlled clinical
studies yet (3). The key prognostic determinants are still
clinico-pathological factors and include tumor stage (14),
patient age, tumor size and location and the response to
neoadjuvant chemotherapy (15). Consequently, all patients
are treated with multiagent chemotherapy irrespective of
its individual efficacy (16). Moreover, new studies about
OS are continuously published and complicate the acquisi-
tion of information for specific research purposes and
questions.
To support the efforts in OS research and biomarker
discovery, we constructed the Osteosarcoma Database.
It provides a structured and review-like overview on cur-
rent OS knowledge with the possibility to rank and sort
the literature according to various parameters, including
therapeutic and prognostic value of specific genes and
microRNAs and the type of samples used. Information of
genes and microRNAs in OS was collected by automated
literature mining and manual review and annotation of
PubMed abstracts. This information was further enriched
by determining microRNA–target gene interactions (MTIs)
of all collected candidates related to OS.
Database Construction
The Osteosarcoma Database aims to provide a high-
quality collection of genes and microRNAs implicated in
the pathogenesis of OS, reviewed by experts of the field.
The data collection and processing steps are illustrated in
Figure 1. The workflow comprised three major steps: auto-
mated dictionary-based gene and microRNA recognition,
manual review and annotation and data storage. The pipe-
line was based on PubMed abstracts that contained the
keywords ‘osteosarcoma*’ or ‘osteogenicþsarcoma*’ in
their titles and/or abstracts. They were downloaded with
the R package XML (17) via NCBI’s E-utilities. Only
abstracts written in English and involving human data or
specimens were considered. The last download of abstracts
was executed on 29 October 2013. In total, 9908 PubMed
abstracts were obtained and served as initial corpus for
further processing.
Dictionary-based gene and microRNA recognition
To reduce the time-consuming process of manual review
and annotation, a dictionary-based gene and microRNA
recognition was performed on the initial corpus of abstracts.
The dictionary of human genes was compiled from the
Human Genome Organisation (HUGO) gene nomencla-
ture committee (18) and the National Center for
Biotechnology Information (NCBI) Entrez gene database
(19). Official symbols, aliases, synonyms, descriptions,
names and database accessions of all genes were combined
to generate the gene dictionary with the Entrez geneid as
unique identifier. The gene dictionary was extended by
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textual variants of genes (e.g. IL6, IL 6 or IL-6) to be as
complete as possible. Ambiguous synonyms and frequent
English words according to the stop words function of the
R package tm (20) were excluded to avoid inaccurate gene
recognitions. In case of microRNAs, regular expressions
like ‘mir’, ‘miR’, ‘MIR’, ‘miRNA’ and ‘microRNA’ were
used for entity recognition. The miRBase (21) accessions of
mature microRNA sequences served as unique identifiers.
Genes included in the dictionary were identified in the
initial corpus of abstracts by string matching and the
microRNAs by regular expressions using the R package tm
(20). Abstracts without any gene or microRNA occurrence
were excluded from further processing, e.g. abstracts of
epidemiologic studies. The remaining abstracts were
manually reviewed and annotated according to their func-
tional role in the OS.
Manual review and annotation
During the manual review and annotation step, the reviewers
verified the specific genes and microRNAs recognized in the
abstracts. Additionally, information about experimental set-
tings, the biological context and therapeutic and prognostic
impact was marked. The experimental settings comprised
the experimental procedure, name of cell lines and kind of
samples. Abstracts dealing with human OS cell lines but
describing anything but OS biology were excluded.
To provide as much information as possible, we mapped
OS-related genes and microRNAs to external databases like
NCBI Entrez gene (19), Ensembl (22), Online Mendelian
Inheritance in Man (OMIM) (23), Gene Ontology (24),
Kyoto Encyclopedia of Genes and Genomes (KEGG)
Pathway (25) and miRBase (21). Furthermore, the OS-
related literature derived from PubMed (26) was linked to
each gene and microRNA entry.
As microRNA regulation has become a major subject
of OS research, we determined possible MTIs between
OS-related genes and microRNAs. Predicted microRNA
targets were computed by running the local perl scripts tar-
getscan_60.pl and targetscan_61_context_scores.pl that
were downloaded from the TargetScan Web site (http://
www.targetscan.org/) (27). Mature microRNA sequences
Figure 1. Database construction pipeline. The database construction is performed in three major steps: automated dictionary-based literature mining,
data review and annotation by reviewers and external data sources and data storage in a MySQL relational database with Web interface. The whole
pipeline is based on PubMed-derived abstracts related to OS research.
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were gained from miRBase release 20 (21). To obtain
high-efficacy targets, we excluded target predictions with a
context score>0.1 (27).
Data storage
To store and access the collected information on
OS-related genes including their gene products and
microRNAs, we implemented a database and a user-
friendly Web interface. The Osteosarcoma Database is a
MySQL relational database. The database scheme is illus-
trated in Supplementary Figure S1. To easily access
OS-related genes and microRNAs, users can search and
browse via a Web interface at http://osteosarcoma-db.uni-
muenster.de. It is built on PHP and JavaScript. For inter-
active data visualization, we applied tagcanvas (http://
www.goat1000.com/tagcanvas.php) and cytoscapeweb
(28). Alternatively, users can download the Osteosarcoma
Database sql file to perform their own queries. The down-
load link is provided at http://osteosarcoma-db.uni-muen
ster.de/download.php.
Database Description
The Osteosarcoma Database allows retrieving information
of candidate genes including their gene products and
microRNAs associated with the pathogenesis of OS to sup-
port their individual research purposes. Beside gene and
microRNA information derived from external databases,
manual annotations of OS-related abstracts are provided.
Annotations include the number of abstracts focusing
on the specific genes with their gene products and
microRNAs, the experimental procedures conducted in
distinct studies, the potential therapeutic and prognostic
value of genes and microRNAs, the specific data types and
the biological context investigated. Additionally, regula-
tory MTIs between collected microRNAs and genes were
added. Currently, the database contains 911 genes includ-
ing their gene products and 81 microRNAs associated with
osteosarcoma biology according to 1331 abstracts.
Between these microRNAs and genes, we determined 6305
regulatory MTIs due to TargetScan 6 (27).
The database can be searched using the Web interface
(http://osteosarcoma-db.uni-muenster.de) with two pos-
sible input forms depending on the user’s research focus.
For gene search, Entrez geneids and official gene symbols
are accepted. MicroRNAs require miRBase accessions or
names of mature microRNA sequences. A search for word
components is also possible. After submitting the query,
suggestions of genes or microRNAs are presented matching
the search term. Users can select their requested entry and
the results page is displayed.
The main results page lists general information of the
requested gene or microRNA. Underscored entries provide
links to respective external databases. Below the general
gene or microRNA information, a table marks the ab-
stracts describing the gene’s or microRNA’s involvement
in the pathogenesis of OS. The abstracts can be filtered ac-
cording to potential therapeutic and prognostic value and
according to tumor samples. Further annotation of experi-
mental settings and biological contexts is provided for
download using the export button on top of the table. To
note, even if the selection of abstracts was initially based
on gene names, we also included experiments involving
their gene products such as immunohistochemistry and
western blots. However, gene symbols are used as unique
identifiers for each gene and/or gene product. Moreover,
regulatory MTIs of a specific query are accessible via the
MTI button on top of the results page. This button directs
the user to predicted microRNA target gene networks. For
microRNAs, all target genes are visualized, and for genes,
the microRNAs that regulate the respective genes are pre-
sented. The network can be explored by zooming in and
out or drag and drop nodes. Below the network, details of
TargetScan predictions are given. Figure 2 illustrates the
main results page and the MTI network using the example
of the gene CDKN1A.
Alternatively, the user can browse collected genes,
microRNAs and abstracts stored in the database. The last
column of all browse tables provides a link to the main re-
sults page of the respective gene or microRNA. To visually
explore genes including gene products frequently men-
tioned in OS-related literature, a tagcloud of the top genes
was implemented. Just genes mentioned in at least five
PubMed abstracts are visualized as top genes. By clicking
on gene names, the user is again directed to the main
results page for the specific gene.
If we miss specific genes or publications about osteosar-
coma, users are welcome to suggest them to us via a con-
tact form, and we are pleased to add them to the database.
A graphical guide through the Osteosarcoma Database is
available for download on the database Web site at http://
osteosarcoma-db.uni-muenster.de/php/tutorial.pdf.
Discussion and Future Directions
The ongoing research to detect genes or pathways fre-
quently altered in OS and the search for new therapeutic
and prognostic procedures is hampered by the genetic
complexity of OS. It becomes even more complicated be-
cause of the ever increasing literature about studies of OS
that make literature research highly time-consuming.
Therefore, it is necessary to structure the existing know-
ledge of genes and microRNAs associated with OS.
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On that account, we developed the Osteosarcoma
Database to supply a review of the current state of OS
research and made this information easily accessible to
researchers.
Pathway enrichment analysis on osteosarcoma-
related genes
To evaluate the content of the Osteosarcoma Database re-
garding its functional association to cancer, we performed
a KEGG pathway enrichment analysis. All Entrez genes in
the human genome were used as a background set. The
hypergeometric test was computed to find significantly
overrepresented categories (false discovery rate <0.05).
The top 20 enriched pathways are listed in Table 1.
The enrichment results show that the collected OS genes
are overrepresented in cancer-related pathways. This
indicates that in OS, many well-known oncogenes (e.g.
MYC) and tumor suppressor genes (e.g. TP53 and PTEN)
are altered. Furthermore, the TGFB signaling pathway is
discussed for its contribution to tumor suppression and
progression, (29) and the terms apoptosis, cell cycle and
focal adhesion represent key signaling pathways in cancer
(hallmarks of cancer) (30). Interestingly, we also detected
the osteoclast differentiation pathway. In a normal bone,
there is a precisely regulated balance between osteoclastic
and osteoblastic activity. In OS, this critical balance might
be interrupted (31). Taken together, these results indicate
OS to require pathways commonly deregulated in cancer
as well as to feature OS-specific alterations comprising
deregulated osteoclast differentiation.
All properties of OS mentioned earlier are included in
the Osteosarcoma Database in terms of OS-related genes,
supporting the quality of this collection.
Figure 2. Screenshot of the CDKN1A results page. The database screenshots show the main results page of a gene search and the corresponding MTI
network using the example of CDKN1A. (1) The search menu enables the user to search for a gene or microRNA query. (2) Submitting the query de-
livers the results page for the speciﬁc query that shows general information derived from external databases and abstracts associated with the query.
(3) The table of abstracts can be browsed using pagination buttons and (4) ﬁltered according to type of samples, potential prognostic and/or thera-
peutic value or text search within the titles. (5) To receive more manual annotations like experimental settings, biological context and information
about the abstracts, an export button is provided. (6þ 7) The MTI network visually illustrates the possible regulatory relationships of the user’s query.
A detailed description of the prediction results is given in the table below. (8) Again, users are able to export the table and receive additional informa-
tion like UTR coordinates and so on.
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Prognostic or therapeutic value of genes and
microRNAs in osteosarcoma
The ultimate aim of OS research is to understand the
molecular mechanism underlying OS biology that would
imply the discovery of innovative prognostic and/or pre-
dictive biomarkers. The Osteosarcoma Database provides
a table that lists the prognostic and/or therapeutic value of
genes or microRNAs in corresponding PubMed abstracts.
This table can be ranked according to genes or microRNAs
with possible impact. Table 2 presents genes and
microRNAs that might serve as potential biomarkers in
OS. Only genes proposed as candidate markers in at least
five studies are listed. As microRNA research is still a
young field of research, we list all microRNAs with poten-
tial prognostic and predictive impact.
Alkaline phosphatase (ALPL) and lactate dehydrogen-
ase (LDHA) are the only accepted biomarkers with prog-
nostic significance, detectable in the peripheral blood.
Concentrations correlate with tumor burden and an ad-
verse outcome (32, 33). Nevertheless, the remaining genes
and microRNAs are equally promising candidate markers.
For instance, the genes including their gene products EZR
and VEGFA are significantly correlated with meta-
static spread (8, 34), and the ABCB1 gene coding for the
p-glycoprotein seems to be associated with multiple–drug-
resistance (8). Additionally, the table shows two members
of the microRNA family microRNA-34. These family
members are well-characterized tumor suppressors in
many cancers and activate TP53 regulated pathways. This
microRNA family was extensively tested for its therapeutic
use in several tumors and might be the first microRNA
family to reach the clinic (35).
Up to now, the prognostic prediction or therapeutic
stratification of OS is not based on biomarkers. However,
the table suggests many promising candidates that should
be further investigated and sometime enter clinical studies.
Osteosarcoma-related microRNA target gene
regulation
Much attention has been focused on microRNAs in the
pathogenesis of OS as a new tool for assisting prognosis or
therapy. They function through multiple pathways simul-
taneously, which is in accordance with the perspective on
cancer as a disease affecting the whole cellular system. For
the collected data, we determined potential MTIs by using
TargetScan 6 (27). All microRNAs affecting the largest
number of genes (100 targets) are shown in Table 3.
Again, members of the microRNA family mircoRNA-34 are
listed in the table. They regulate the highest number of tar-
get genes collected in the Osteosarcoma Database support-
ing a crucial role in OS as well as in other cancer types.
Further, the remaining microRNAs are also known to func-
tion as tumor suppressors or oncomirs, e.g. the microRNA
families microRNA-29 and -15. Both families have several
members involved in various cancer subtypes (36, 37).
Table 1. KEGG pathway enrichment analysis
ID KEGG pathway Number of genes Number of genes in pathway P-value FDRa
hsa05200 Pathways in cancer 158 327 5.7410–48 1.1110–45
hsa05215 Prostate cancer 59 89 8.8310–28 8.5710–26
hsa05219 Bladder cancer 33 42 9.6210–20 6.2210–18
hsa05212 Pancreatic cancer 44 70 1.3010–19 6.3110–18
hsa04510 Focal adhesion 82 200 4.5810–19 1.7810–17
hsa05222 Small-cell lung cancer 46 85 8.3910–17 2.6210–15
hsa05220 Chronic myeloid leukemia 42 73 9.4510–17 2.6210–15
hsa05210 Colorectal cancer 38 62 1.4610–16 3.5510–15
hsa04110 Cell cycle 58 128 3.7410–16 8.0710–15
hsa04350 TGF-beta signaling pathway 44 85 3.5510–15 6.8910–14
hsa05223 Non-small-cell lung cancer 33 54 1.7210–14 3.0410–13
hsa04115 p53 signaling pathway 38 69 2.0110–14 3.2510–13
hsa04210 Apoptosis 44 89 3.1210–14 4.6610–13
hsa05214 Glioma 36 65 7.8510–14 1.0910–12
hsa05213 Endometrial cancer 31 52 2.8610–13 3.7010–12
hsa05218 Melanoma 37 71 4.4610–13 5.4110–12
hsa05142 Chagas’ disease (American trypanosomiasis) 46 104 1.3710–11 1.5710–11
hsa05221 Acute myeloid leukemia 31 58 1.5310–11 1.6510–10
hsa04380 Osteoclast differentiation 50 128 4.0410–11 4.1210–10
hsa04012 ErbB signaling pathway 39 87 4.3910–11 4.2610–10
The table shows the results of the hypergeometric test of KEGG pathways.
aFDR, false discovery rate.
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As already mentioned, microRNA research is a young
field and not much is known about their function in OS.
Thus, we provide detailed and up-to-date networks about
possible MTIs to researchers for hypothesis generation and
testing of individual models.
Future directions
Currently, the Osteosarcoma Database focuses on genes
including their gene products and microRNAs associated
with OS development and progression. However, the OS is
a complex tumor with a huge amount of genomic instability
that influences the expression and function of several genes
and microRNAs. Hence, genomic alterations need to be
added in future versions. We plan to include already known
genomic positions marking regions of copy number vari-
ations, allelic imbalances and translocations, as it has been
shown that structural chromosomal alterations could be
used to predict prognosis at diagnosis (2). Moreover, obser-
vations of genome-wide changes from next-generation
sequencing studies might further obtain new insights into
OS biology and must be added as soon as they are available.
We plan to update the database biannually to provide
state-of-the-art knowledge and keep track of improve-
ments in the field. We hope that the Osteosarcoma
Database will serve as a platform for information and hy-
pothesis generation for the research community that helps
to uncover the complexity of OS.
Supplementary data
Supplementary Data are available at Database Online.
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MIMAT0000084 hsa-miR-27a-3p 117
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